136 related articles for article (PubMed ID: 16417966)
21. 5-Hydroxyeicosatetraenoic Acid Controls Androgen Reduction in Diverse Types of Human Epithelial Cells.
Hardaway AL; Goudarzi M; Berk M; Chung YM; Zhang R; Li J; Klein E; Sharifi N
Endocrinology; 2022 Nov; 164(1):. PubMed ID: 36412122
[TBL] [Abstract][Full Text] [Related]
22. Role of Human Aldo-Keto Reductases in the Nitroreduction of 1-Nitropyrene and 1,8-Dinitropyrene.
Su AL; Mesaros CA; Krzeminski J; El-Bayoumy K; Penning TM
Chem Res Toxicol; 2022 Dec; 35(12):2296-2309. PubMed ID: 36399404
[TBL] [Abstract][Full Text] [Related]
23. Development of new steroid-based hydrazide and (thio)semicarbazone compounds with anticancer properties.
Janković Ð; Šestić TL; Bekić SS; Savić MP; Ćelić AS; Scholda J; Kopp F; Marinović MA; Petri ET; Ajduković JJ
J Steroid Biochem Mol Biol; 2024 May; ():106545. PubMed ID: 38762058
[TBL] [Abstract][Full Text] [Related]
24. A novel selective AKR1C3-activated prodrug AST-3424/OBI-3424 exhibits broad anti-tumor activity.
Meng F; Li WF; Jung D; Wang CC; Qi T; Shia CS; Hsu RY; Hsieh YC; Duan J
Am J Cancer Res; 2021; 11(7):3645-3659. PubMed ID: 34354865
[TBL] [Abstract][Full Text] [Related]
25. Computer aided screening of inhibitors to 5-α reductase type 2 for prostate cancer.
Bhattacharjee B; Talambedu U; Sadegh S; Goyal AK; Pande V; Nagaveni MB; Patil VM; Jayadev J; Middha SK
Bioinformation; 2011; 6(7):262-5. PubMed ID: 21738326
[TBL] [Abstract][Full Text] [Related]
26. Involvement of an aldo-keto reductase (AKR1C3) in redox cycling of 9,10-phenanthrenequinone leading to apoptosis in human endothelial cells.
Matsunaga T; Arakaki M; Kamiya T; Endo S; El-Kabbani O; Hara A
Chem Biol Interact; 2009 Sep; 181(1):52-60. PubMed ID: 19442656
[TBL] [Abstract][Full Text] [Related]
27. AKR1C3 as a target in castrate resistant prostate cancer.
Adeniji AO; Chen M; Penning TM
J Steroid Biochem Mol Biol; 2013 Sep; 137():136-49. PubMed ID: 23748150
[TBL] [Abstract][Full Text] [Related]
28. Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progression.
Dozmorov MG; Azzarello JT; Wren JD; Fung KM; Yang Q; Davis JS; Hurst RE; Culkin DJ; Penning TM; Lin HK
BMC Cancer; 2010 Dec; 10():672. PubMed ID: 21134280
[TBL] [Abstract][Full Text] [Related]
29. The aldo-keto reductases (AKRs): Overview.
Penning TM
Chem Biol Interact; 2015 Jun; 234():236-46. PubMed ID: 25304492
[TBL] [Abstract][Full Text] [Related]
30. Kinetic and structural evidence for a sequential ordered Bi Bi mechanism of catalysis by Saccharomyces cerevisiae myristoyl-CoA:protein N-myristoyltransferase.
Rudnick DA; McWherter CA; Rocque WJ; Lennon PJ; Getman DP; Gordon JI
J Biol Chem; 1991 May; 266(15):9732-9. PubMed ID: 2033063
[TBL] [Abstract][Full Text] [Related]
31. Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.
Penning TM
Expert Opin Ther Pat; 2017 Dec; 27(12):1329-1340. PubMed ID: 28895472
[TBL] [Abstract][Full Text] [Related]
32. Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer.
Liedtke AJ; Adeniji AO; Chen M; Byrns MC; Jin Y; Christianson DW; Marnett LJ; Penning TM
J Med Chem; 2013 Mar; 56(6):2429-46. PubMed ID: 23432095
[TBL] [Abstract][Full Text] [Related]
33. Crystal structures of three classes of non-steroidal anti-inflammatory drugs in complex with aldo-keto reductase 1C3.
Flanagan JU; Yosaatmadja Y; Teague RM; Chai MZ; Turnbull AP; Squire CJ
PLoS One; 2012; 7(8):e43965. PubMed ID: 22937138
[TBL] [Abstract][Full Text] [Related]
34. Catalytic mechanism and substrate selectivity of aldo-keto reductases: insights from structure-function studies of Candida tenuis xylose reductase.
Kratzer R; Wilson DK; Nidetzky B
IUBMB Life; 2006 Sep; 58(9):499-507. PubMed ID: 17002977
[TBL] [Abstract][Full Text] [Related]
35. An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies.
Byrns MC; Steckelbroeck S; Penning TM
Biochem Pharmacol; 2008 Jan; 75(2):484-93. PubMed ID: 17950253
[TBL] [Abstract][Full Text] [Related]
36. AKR1C3, a crucial androgenic enzyme in prostate cancer, promotes epithelial-mesenchymal transition and metastasis through activating ERK signaling.
Wang B; Gu Y; Hui K; Huang J; Xu S; Wu S; Li L; Fan J; Wang X; Hsieh JT; He D; Wu K
Urol Oncol; 2018 Oct; 36(10):472.e11-472.e20. PubMed ID: 30139661
[TBL] [Abstract][Full Text] [Related]
37. AKR1C3 (type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase): Roles in malignancy and endocrine disorders.
Penning TM
Mol Cell Endocrinol; 2019 Jun; 489():82-91. PubMed ID: 30012349
[TBL] [Abstract][Full Text] [Related]
38. AKR1C3 in carcinomas: from multifaceted roles to therapeutic strategies.
Li M; Zhang L; Yu J; Wang X; Cheng L; Ma Z; Chen X; Wang L; Goh BC
Front Pharmacol; 2024; 15():1378292. PubMed ID: 38523637
[TBL] [Abstract][Full Text] [Related]
39. Regulatory genes in the androgen production, uptake and conversion (APUC) pathway in advanced prostate cancer.
McSweeney S; Bergom HE; Prizment A; Halabi S; Sharifi N; Ryan C; Hwang J
Endocr Oncol; 2022 Jan; 2(1):R51-R64. PubMed ID: 37435458
[TBL] [Abstract][Full Text] [Related]
40. Preclinical and Clinical Research Models of Prostate Cancer: A Brief Overview.
Basak D; Gregori L; Johora F; Deb S
Life (Basel); 2022 Oct; 12(10):. PubMed ID: 36295041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
